Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxaliplatin
Drug ID BADD_D01633
Description Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.
Indications and Usage Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Marketing Status approved; investigational
ATC Code L01XA03
DrugBank ID DB00526
KEGG ID D01790
MeSH ID D000077150
PubChem ID 9887053
TTD Drug ID D0Y3ME
NDC Product Code 0703-3986; 13808-502; 0955-1733; 25021-233; 68083-171; 72603-101; 0955-1727; 57884-0017; 63592-0700; 50742-406; 55150-332; 67184-0501; 68083-170; 68083-176; 0955-1731; 72659-865; 43066-014; 68001-468; 71288-101; 82920-704; 16729-332; 45963-611; 67184-0502; 67184-0509; 0781-3317; 0781-9317; 67457-469; 0703-3985; 54875-0006; 67184-0510; 67457-442; 68083-314; 72266-126; 0781-3315; 50742-405; 71288-149; 72266-162; 0781-9315; 55150-331; 61703-363; 63323-750; 67184-0508; 72266-125; 72266-161; 72603-301; 79672-825; 0955-1725; 53104-7649; 67184-0007; 68554-0083; 60505-6132; 68083-177; 79672-826; 14778-0404; 49812-0075; 43066-018
UNII 04ZR38536J
Synonyms Oxaliplatin | Oxalato-(1,2-cyclohexanediamine)platinum II | Oxaliplatin, (SP-4-2-(1R-trans))-isomer | L-OHP Cpd | Platinum(II)-1,2-cyclohexanediamine Oxalate | 1,2-Diaminocyclohexane Platinum Oxalate | 1,2 Diaminocyclohexane Platinum Oxalate | 1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II) | Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) | Oxaliplatine | Eloxatine | Eloxatin | Oxaliplatin, (SP-4-3-(cis))-isomer | ACT 078 | ACT-078 | ACT078 | Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II) | Oxaliplatin, (SP-4-2-(1S-trans))-isomer
Chemical Information
Molecular Formula C8H14N2O4Pt
CAS Registry Number 61825-94-3
SMILES C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemolysis01.06.04.0020.000616%
Haemolytic anaemia01.06.03.0020.001119%Not Available
Haemolytic uraemic syndrome20.01.03.011; 01.06.02.0010.000560%
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.004--Not Available
Haemorrhagic stroke17.08.01.011; 24.07.04.0140.000168%Not Available
Haemorrhoids24.10.02.002; 07.15.03.001--
Headache17.14.01.001--
Hemiparesis17.01.04.0010.001254%
Hepatic atrophy09.01.08.0040.000336%Not Available
Hepatic cirrhosis09.01.04.0010.000660%Not Available
Hepatic failure09.01.03.0020.001030%
Hepatic fibrosis24.08.06.002; 09.01.04.0020.000526%Not Available
Hepatic steatosis14.08.04.005; 09.01.07.0030.000582%Not Available
Hepatic vein thrombosis24.01.03.004; 09.01.06.0120.000895%Not Available
Hepatitis09.01.07.0040.001007%Not Available
Hepatitis acute09.01.07.0050.000448%Not Available
Hepatocellular injury09.01.07.0080.000560%Not Available
Hepatomegaly09.01.05.0010.000358%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
Hiccups22.12.01.001; 07.01.06.0090.000224%
Hyperammonaemia14.10.01.001; 09.01.02.0020.000224%Not Available
Hyperbilirubinaemia09.01.01.003; 14.11.01.010; 01.06.04.0030.000280%Not Available
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.0280.012390%
Hyperpyrexia08.05.02.0020.000392%Not Available
Hypersensitivity10.01.03.0030.010700%
Hypersensitivity vasculitis24.12.04.013; 23.06.02.005; 10.02.02.017; 01.01.04.0080.000224%Not Available
Hypertension24.08.02.0010.005988%
Hypertensive crisis24.08.01.0010.002071%Not Available
Hyperthermia08.05.01.001; 12.05.01.0020.001455%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene